A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL 3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease
Latest Information Update: 18 Sep 2021
At a glance
- Drugs VSL 3 (Primary) ; Azathioprine; Mesalazine
- Indications Crohn's disease
- Focus Biomarker; Pharmacodynamics
- 12 Aug 2014 Biomarkers information updated
- 18 Mar 2013 Planned End Date changed from 1 Dec 2012 to 1 Feb 2015 as reported by ClinicalTrials.gov.
- 12 Jul 2012 New trial record